ESC 365 - CSK9 inhibitors and cardiovascular outcomes – Represented in New England Journal of Medicine by the FOURIER and SPIRE trials.

ESC Premium Access

CSK9 inhibitors and cardiovascular outcomes – Represented in New England Journal of Medicine by the FOURIER and SPIRE trials.

Session: Highlights from the New England Journal of Medicine: editors’ choice

Topic: Miscellaneous

Speaker: Professor M. Sabatine (Boston, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

25 presentations

1 follower

3 more presentations in this session

Bioresorbable vascular scaffolds for PCI – Represented in New England Journal of Medicin by the ABSORB III and AIDA trials.

Speaker: Doctor J. Wykrzykowska (Groningen, NL)

ICD implantation for non-ischaemic cardiomyopathy – Represented in New England Journal of Medicine by the DANISH trial.

Speaker: Professor L. Kober (Copenhagen, DK)

Prevention of recurrent venous thromboembolism – Represented in New England Journal of Medicine by several trials, including EINSTEIN, AMPLIFY, WARFASA, Hokusai-VTE, and others.

Speaker: Doctor J. Weitz (Hamilton, CA)

Access the full session

Highlights from the New England Journal of Medicine: editors’ choice

Speakers: Professor M. Sabatine, Doctor J. Wykrzykowska, Professor L. Kober, Doctor J. Weitz

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources